Wuxi AppTec Co Ltd Class A 603259
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
-
WuXi AppTec Shares Surge on Strong Earnings, Higher Guidance
-
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
-
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
WuXi AppTec Shares Rally Amid Sectorwide Gains After Tech Selloff, China Policy Support
-
Alibaba, Baidu Reject Inclusion on Pentagon Military-Ties List — Update
-
Alibaba, Baidu Deny Chinese Military Ties, Push Back Against Inclusion to Pentagon List
Trading Information
- Previous Close Price
- CN¥158.86
- Day Range
- CN¥155.92–159.68
- 52-Week Range
- CN¥87.09–173.60
- Bid/Ask
- CN¥156.66 / CN¥156.67
- Shares Outstanding
- 3.03B
- Market Cap
- CN¥474.89B
- Volume/Avg
- 26M / 61M
Key Statistics
- Price/Earnings (Normalized)
- 22.36
- Price/Sales
- 8.60
- Dividend Yield (Trailing)
- 1.33%
- Dividend Yield (Forward)
- 1.33%
- Dividend Payment Schedule
- May, Sep
- Total Yield
- 1.33%
Company Profile
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Large Core
- Total Number of Employees
- 33,834
- Website
- https://www.wuxiapptec.com
Valuation
|
Metric
|
603259
|
|---|---|
Price/Earnings (Normalized) | 22.36 |
Price/Book Value | 5.61 |
Price/Sales | 8.60 |
Price/Cash Flow | 20.47 |
Price/Earnings
603259
Financial Strength
|
Metric
|
603259
|
|---|---|
Quick Ratio | 2.01 |
Current Ratio | 2.54 |
Interest Coverage | 111.94 |
Quick Ratio
603259
Profitability
|
Metric
|
603259
|
|---|---|
Return on Assets (Normalized) | 21.59% |
Return on Equity (Normalized) | 29.36% |
Return on Invested Capital (Normalized) | 25.54% |
Return on Assets
603259
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|bt?v><& | LOCK|zXk | $227B | |||
| Danaher Corp
DHR
| LOCK|P>TY!P@ | LOCK|<&M | $143B | |||
| IQVIA Holdings Inc
IQV
| LOCK|J?lL^c | LOCK|Z>l^ | $44B | |||
| Agilent Technologies Inc
A
| LOCK|@x%!SH> | LOCK|Jy | $41B | |||
| Waters Corp
WAT
| LOCK|@B##!& | LOCK|hS | $40B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|!@!!!Z@V | LOCK|s$ | $40B | |||
| Illumina Inc
ILMN
| LOCK|!Fv>YpR | LOCK|>l!< | $31B | |||
| Quest Diagnostics Inc
DGX
| LOCK|wm!nHj | LOCK|Hh^<s | $26B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|&<?&v!TQ | LOCK|pmS%l | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|G^rfW%P | LOCK|^VGk | $26B |
United States